A well-known collaborator with Eli Lilly – BioAge Labs is focusing on developing an anti-obesity drug for the elderly "by targeting the biology of human ageing", the biopharmaceutical start-up said.

Our round-up of recent biotech financings is headed by a $254 million private financing for cancer blood test specialist Freenome, with sizeable rounds for Cogent Biosciences, BioAge Labs ...

BioAge has initiated a mid-stage trial of its drug in combination with Zepbound and also plans to test it in combination with Wegovy in the first half of 2025. Part of the proceeds from the IPO ...

RICHMOND, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases ...